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ABSTRACT 
Objective: Bartter’s syndrome is one of the most impor-
tant inherited diseases that cause chloride leak. The objective 
of this study was to report the follow-up of ten patients with 
the syndrome.
Methods: This observational study was based on the 
review of medical charts reporting the metabolic features, 
creatinine clearance, nutritional and anthropometric assess-
ment of ten patients with Bartter’s syndrome followed at 
the Nephrology Service of the Universidade Federal de São 
Paulo, in their first and last medical appointments, after a 
mean follow-up period of 43 months (3-76 months). During 
the follow-up, the management included the administration 
of potassium (100%) and magnesium (60%) supplements, 
non-steroidal anti-inflammatory agents (90%), angiotensin-
converting enzyme inhibitors (40%) and spironolactone 
(50%). Statistical analysis was performed comparing the 
results of first versus last clinical appointment by non-
parametric Wilcoxon test.
Results: Improvement of serum electrolytes and statural 
growth after the treatment was observed but only serum 
potassium [3.05mEq/L versus 3.25 mEq/L (p=0.01)] and 
weigh-for-age Z-score [initial median -2.47 versus -1.35 
(p=0.02)] improved significantly. Out of the ten patients 
studied, two presented decrease of creatinine clearance with 
chronic kidney disease at stage 2 at the end of the follow-
up. These patients had already started the follow-up with 
decreased creatinine clearance. 
Conclusions: There is a need of early treatment of pa-
tients with Bartter’s syndrome in order to improve their 
electrolytes and nutritional condition without compromis-
ing the creatinine clearance.
Key-words: metabolic alkalosis; failure to thrive; 
polyuria; hypokalemia; developmental disabilities; Bartter 
syndrome.
ReSumo
Objetivo: A síndrome de Bartter é uma doença rara, 
porém uma das mais frequentes condições congênitas per-
dedoras de cloro. Este trabalho teve como objetivo relatar a 
evolução de dez pacientes com a síndrome.
Métodos: Estudo observacional, descritivo, realizado 
pela análise de prontuários médicos relatando o perfil me-
tabólico, a depuração de creatinina, o estado nutricional e 
pôndero-estatural de dez pacientes atendidos no Serviço 
de Nefrologia da Universidade Federal de São Paulo com 
características clínico-laboratoriais da síndrome de Bartter, 
seguidos por um período médio de 43 meses (3-76 meses). 
Durante o acompanhamento, o tratamento consistiu na ad-
ministração de suplemento de potássio (100%), magnésio 
(60%), anti-inflamatórios não hormonais (90%), inibidores 
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de enzima conversora de angiotensina (40%) e espirono-
lactona (50%). A análise estatística constou da comparação 
dos dados da primeira e da última consulta, utilizando-se o 
teste de Wilcoxon.
Resultados: Observou-se melhora dos valores absolutos 
dos itens avaliados e do desenvolvimento pôndero-estatural 
com a terapêutica empregada, porém apenas a calemia 
[mediana inicial 3,05mEqL e final 3,25mEqL (p=0,01)] 
e o escore Z de peso idade [mediana inicial -2,47 e final 
-1,35 (p=0,02)] apresentaram melhora significante. Dos 
dez pacientes estudados, dois apresentavam diminuição da 
depuração de creatinina com doença renal crônica estágio 
2 no final do acompanhamento (ambos tinham iniciado o 
acompanhamento com depuração renal comprometida). 
Conclusões: Há necessidade da instituição terapêutica 
precoce para melhorar os níveis séricos dos eletrólitos e o 
estado nutricional dos pacientes acometidos, sem compro-
meter a depuração de creatinina.
Palavras-chave: alcalose metabólica; insuficiência de 
crescimento; poliúria; hipopotassemia; deficiências do de-
senvolvimento; síndrome de Bartter. 
ReSumeN
Objetivo: El síndrome de Bartter (SB) es una enfermedad 
rara, pero una de las más frecuentes condiciones congénitas 
perdedoras de cloro. Este trabajo tiene por objetivo relatar 
la evolución de diez pacientes con SB.
Métodos: Estudio observacional, descriptivo, obtenido 
mediante análisis de prontuarios médicos. Relata el perfil 
metabólico, la depuración de creatinina, el estado nutricio-
nal y ponderoestatural de los diez pacientes atendidos en el 
ambulatorio de Tubulopatías de Universidade Federal de 
São Paulo con características clínico-laboratoriales de SB, 
seguidos por un periodo mediano de 43 meses (3-76 meses). 
Durante el seguimiento se practicó protocolo de tratamiento 
que consistió en la administración de suplemento de potasio 
(100%), magnesio (60%), anti-inflamatorios no hormonales 
(90%), inhibidores de enzima convertidora de angiotensina 
(40%) y espironolactona (50%). Se consideraron criterios 
de exclusión la presencia de alteraciones séricas y urinarias 
no compatibles con SB. El análisis estadístico constó de la 
comparación de datos de la primera y la última consulta, 
utilizándose la prueba de Wilcoxon.
Resultados: Se observó mejora numérica de los valores 
absolutos de los ítems evaluados y del desarrollo ponderoes-
tatural con la terapéutica utilizada, pero solamente la calemia 
[mediana inicial 3,05mEq/L y final 3,25mEq/L (p=0,01)] y 
el escore Z de peso/edad [mediana inicial -2,47 y final 1,35 
(p=0,02)] presentaron mejora significante. De los 10 pacien-
tes estudiados, dos presentaban reducción de la depuración 
de creatinina con enfermedad renal crónica etapa 2 y en el 
final del seguimiento (ambos habían iniciado el seguimiento 
con depuración renal comprometida). 
Conclusiones: Los datos enfatizan la necesidad de la ins-
titución terapéutica precoz para mejorar los niveles séricos 
de los electrólitos y el estado nutricional, sin comprometer 
la depuración de creatinina.
Palabras clave: alcalosis metabólica; insuficiencia de 
crecimiento; poliuria; hipocalemia; deficiencia del desarrollo; 
síndrome de Bartter. 
Introduction
Bartter’s syndrome (BS), which was first described in 
1962, is characterized by hypokalemic, hypochloremic and 
hyperreninemic metabolic alkalosis, with normal blood 
pressure. Since its initial description, several forms of clinical 
presentation demonstrating the phenotypic heterogeneity 
of this disease have been observed(1,2). In terms of clinical 
aspects, most patients are malnourished and have severe 
growth retardation (below the 3rd percentile)(3,4). In addition, 
these patients present with polyuria, polydipsia, and 
dehydration, which occur in the neonatal period or early in 
life(5). Studies of growth and development in patients with BS 
have suggested that severe growth retardation occurs during 
childhood and that normal height is rarely reached(6-8). 
Bettinelli et al reported that the height of 18 children with 
BS ranged from -4.9 to 0.9 standard deviations, and 11 of 
these children had height below -2 standard deviations(8).
Treatment includes non-hormonal anti-inflammatory 
agents and potassium replacement aiming to reduce or 
normalize the water-electrolyte balance of these patients, 
showing variable responses to therapeutic support, water 
and electrolyte replacement(9). Schachter et al reported 
that the four patients they assessed had worsening of 
renal clearance after the association of non-hormonal anti-
inflammatory drugs(9).
The objective of the present study was to assess the impact 
of drug treatment on the metabolic profile and height and 
weight development of patients with BS treated between 
2000 and 2006.
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method
During this observational and descriptive study, we analyzed 
the medical records of ten children with BS seen at the outpatient 
clinic of tubulopathy of the Unit of Pediatric Nephrology, 
Department of Pediatrics, Universidade Federal de São Paulo 
(Unifesp), between March 2000 and October 2006.
Considering the clinical and laboratory findings, 
BS diagnosis was established based on the criteria of 
hypokalemic and hypochloremic metabolic alkalosis, with 
increased prostaglandin and renin, and urinary losses of 
potassium, sodium, and chloride. All patients diagnosed 
with BS during the study period or who were being followed 
up at the outpatient clinic aged between three and 164 
months (age at the beginning of treatment) were included in 
the present study. Exclusion criteria were presence of serum 
and urinary changes incompatible with BS. 
These patients underwent serum tests in order to assess 
their levels of bicarbonate, potassium, pH, sodium, chloride, 
and magnesium, microalbuminuria in isolated urine sample 
and estimated creatinine clearance according to Schwartz 
formula(10). As for creatinine, it was measured in blood and 
urine samples using the alkaline picrate method according 
to the modified Jaffé reaction(11). Serum creatinine was 
used to calculate estimated creatinine clearance according 
to Schwartz formula(10). Urinary creatinine was used to 
calculate the relationship with the electrolytes. Venous 
serum bicarbonate was measured using a blood gas analyzer 
by means of the selective method (Ise) with the Advia 1650 
Bayer device and normal values were set at 24-28mEq/L. 
Serum pH was measured using a blood gas analyzer by 
means of the selective method (Ise) with the Advia 1650 
Bayer device, and normal values were set at 7.35-7.45. 
Electrolyte concentrations of serum sodium, potassium, 
and chloride were evaluated by the selective method (Ise), 
using the Advia 1650 Bayer device, and the normal value 
for sodium serum was 137-142mEq/L, while for potassium 
serum it was 3.5-5.2mEq/L and for chloride serum it was 98-
107mEq/L. Serum magnesium level was measured using the 
colorimetric method (xylidyl blue), and the reference value 
was 1.8-2.2mEq/L. Microalbuminuria in an isolated urine 
sample was measured using immunoturbidimetry(12). 
Nutritional assessments were performed by nutritionists 
at the Unit of Pediatric Nephrology, using the direct method 
based on anthropometric measurements. Nutritional status 
was measured using body mass index (BMI), BMI z-score, 
weight for age and height for age z-scores for children based 
on weight, height, sex and age of children and adolescents. 
These data were calculated using the software provided by 
the World Health Organization (WHO), Anthro and Anthro 
plus, which use the WHO curves as reference(13). The WHO 
curves were used according to age group.
All patients underwent nutritional assessments during 
follow-up visits. The results of the assessment of the first 
visit were recorded and then the evolution was demonstrated 
based on the results of the last individual visit. It is 
important to emphasize that none of the visits included in 
the present study were emergency room visits, all of them 
being routine outpatient follow-up visits. Because BS is a 
rare pathology, we did not define minimal follow-up period 
as an exclusion criterion.
The treatment protocol included the use of non-hormonal 
anti-inflammatory drugs, especially indomethacin and 
potassium and/or magnesium replacement to keep the 
metabolic profile at normal or nearly normal levels in all 
patients. Other drugs, such as angiotensin I-converting 
enzyme inhibitor and spironolactone, were associated in some 
patients selected according to their clinical evaluation. 
The statistical analysis consisted of comparison of each 
parameter at baseline and in the last follow-up visit, using 
means, medians, and minimum and maximum standard 
deviations to summarize and describe the patients. In order 
to compare quantitative variables at two different study 
times (beginning and end), we used the Wilcoxon test, 
with a limit of 5% (p<0.05) to reject the null hypothesis. 
To demonstrate the temporal evolution of serum potassium 
serum levels, we designed a graph showing the values of 
each patient measured in semi-annual visits.
This study was approved by the Research Ethics 
Committee of Unifesp. The patients were not asked to sign 
a written consent form because this was a retrospective 
study and the Medical Ethics Committee of Unifesp did 
not require it.
Results
We evaluated ten children with BS who were followed 
up at our outpatient clinic during the study period. There 
were seven males and three females. The follow-up period 
ranged from three months to 76 months, with a mean of 44 
months and median of 55 months.  
The patients’ age at the beginning of the follow-up ranged 
from three to 164 months, with a mean of 61 months. At 
the end of the study, the patients were eight to 230 months 
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old, with a mean age of 105 months. The onset of symptoms 
occurred in the neonatal period in one case, in the infant 
age group in seven patients, and in the preschool period in 
two children.
Of the ten patients, two had decreased creatinine clearance 
with chronic kidney disease stage 2 and 3 (patients 2 and 
6) at the end of the follow-up period. These patients had 
already started the follow-up showing impaired renal 
clearance (stage 2).
In our sample, seven children used indomethacin during 
the follow-up period, two had previously used this drug 
and one did not use it. The medication dose ranged from 
0.5 to 6.4mg/kg/day, and the mean dose was 2.2mg/kg/day. 
Among those who used indomethacin, two discontinued 
the medication because of gastrointestinal effects, but one 
patient resumed its use at low doses. Two patients who 
started being treated with indomethacin at other health care 
facility had upper gastrointestinal bleeding and epigastric 
pain and replaced indomethacin with diclofenac. These 
patients started being followed up at our outpatient clinic 
while using diclofenac. The medication dose ranged from 1.5 
to 7.5mg/kg/day, and the mean dose was 4.4mg/kg/day.
Regarding the use of nimesulide, only one child received 
this drug because of side effects caused by indomethacin. The 
Chart 1 – Variation of the serum potassium levels of patients during follow-up (Each line represents one patient). 
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
1 2 3 4 5 6 7 8 9 10 11
Visit (mean interval between each visit = 6 months)
Se
ru
m
 p
ot
as
si
um
 (m
Eq
/L
)
Table 1 - Patients’ laboratory and nutritional data
P: descriptive level of Wilcoxon’s test; H/A z-score: height for age z-score; W/A z-score: weight for age z-score; BMI z-score: body mass index 
z-score; min: minimum, max: maximum.
Laboratory and nutritional data Baseline median (min/max) Final median (min/max) p
Creatinine Clearance  (ml/min/1.73m2 ) 82 (59/154) 101 (53/160) 0.959
Microalbuminuria  (ug/min) 52 (1/311) 19 (0/288) 0.128
Serum pH 7.45 (7.25/7.71) 7.39 (7.30/7.55) 0.208
Serum bicarbonate (mEq/L ) 28 (24/44) 26 (22/34) 0.440
Serum potassium (mEq/L ) 3.0 (2.0/4.0) 3.2 (2.0/5.0) 0.010
Serum chloride (mEq/L ) 92 (50/108) 99 (91/118) 0.079
Serum sodium (mEq/L ) 136 (121/143) 138 (132/144) 0.139
Serum magnesium (mEq/L ) 1.8 (1/3) 1.7 (2/3) 0.406
H/A z-score -1.3 (-3.5/1.3) -0.7 (-1.7/1.1) 0.114
W/A z-score -2.5 (-3.8/-2.0) -1.3 (-2.8/0.6) 0.028
BMI z-score -2.1 (-4.2/2.0) -1.3 (-2.8/0.8) 0.264
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dose used was 5.2mg/kg/day. One patient replaced the anti-
inflammatory used with rofecoxib to reduce gastrointestinal 
effects of the first drug. The medication dose for this patient 
ranged from 1.3 to 11.6mg/kg/day, and the mean dose was 
9.1mg/kg/day.
Spironolactone was administered to five children at doses 
of 0.5 to 6mg/kg/day, and the mean dose was 2.4mg/kg/
day. Angiotensin I-converting enzyme inhibitor was given 
to four patients at doses ranging from 0.3 to 4.9mg/kg/day 
and a mean dose of 1.21mg/kg/day.
All patients required some type of oral potassium 
replacement (0.1 to 44mEq/kg/day, mean of 5mEq/kg/day). 
Six patients required replacement of magnesium at some 
point of the follow-up period, with doses of 1.7 to 24.9mg/
kg/day and a mean dose of 10.2mg/kg/day. 
There was a trend of improvement of serum bicarbonate, 
pH, and electrolytes, without changes in the creatinine 
clearance; however, only the increase in the serum 
potassium level was statistically significant, even when 
using anti-inflammatory drugs as shown in Table 1. Chart 
1 shows a trend to improved levels of serum potassium, 
evidencing an individual variation during follow-
up. Furthermore, there was a statistically significant 
improvement between baseline and final values of weight 
for age z-score (Table 1).
Discussion
BS is one of the major causes of congenital chloride-
losing diarrhea. This disorder has a heterogeneous spectrum, 
considering both clinical and laboratory factors. The early 
identification of this pathology is an important strategy for 
preventing morbidity and mortality, especially with regard 
to factors that are potentially preventable.
Five genetic variants of SB have been described. All 
these diseases are characterized by autosomal recessive 
transmission, except for type V, being caused by homozygous 
or heterozygous mutations directly or indirectly involving 
proteins responsible for the reabsorption of chloride in the 
thick ascending limb of loop of Henle(14).  
Since the first report on SB, clinical descriptions of 
patients have suggested that this disease is phenotypically 
heterogeneous. Throughout the years, two phenotypic 
groups have been described to encompass the gene mutations 
linked to BS: neonatal (NNBS) and classic (CBS). In the 
neonatal form, symptoms usually start before birth with the 
development of polyhydramnios between 23 and 30 weeks of 
gestation. After birth, the following symptoms may develop: 
prematurity, polyuria, hypercalciuria, and nephrocalcinosis. 
One exception to this neonatal evolution is the NNBS type 
IV, which is associated with a mutation in the BSND gene. 
In this case, in addition to the findings of NNBS, patients 
also have deafness without nephrocalcinosis. On the other 
hand, the classic form affects infants and preschoolers with 
symptoms similar to but less severe than those present in the 
NNBS, growth deficiency, dehydration, and hypercalciuria 
without nephrocalcinosis(15). In our sample, there was one 
case with onset of symptoms during the neonatal period, 
associated with hypoacusis and hypercalciuria without 
nephrocalcinosis; seven patients were infants and two 
were preschoolers. The neonatal case may be related to the 
mutation in the BSND gene; however, further molecular 
investigation should be conducted for more detailed 
information.
The development of chronic renal failure has been 
described in patients with BS, being caused by changes 
in the glomeruli and interstitium, secondary to the long 
period of hypokalemia and decreased renal perfusion, with 
repeated episodes of ischemic injury as a consequence of 
hypovolemia(16,17). The two patients who showed worsening 
renal function at the end of the follow-up period started being 
followed up with some degree of renal function impairment, 
probably secondary to episodes of acute kidney injury and 
metabolic disorder before the diagnosis. In general, we did 
not find worsening of the creatinine clearance during the 
follow-up period in our sample.
BS belongs to a small group of tubulopathies 
characterized by a decrease in NaCl transport in renal distal 
nephron(18). As a consequence, patients present with typical 
characteristics, including salt wasting, hypokalemic 
metabolic alkalosis, hyperreninemic hyperaldosteronism 
with normal blood pressure and alkaline urine pH. Studies 
on growth and development of patients with BS have 
suggested that there may be severe growth retardation in 
infants and preschoolers. According to Rudin, patients 
with BS may be underweight for their age and they 
rarely reach normal height(15,17). Longitudinal growth 
retardation is a common symptom in diseases associated 
with hypokalemia in childhood. In the present study, 
despite the small number of patients, we found that the 
metabolic profile and weight and height deficit can be 
improved or recovered after the beginning of specific 
treatment. We found that in general there was difference 
between the baseline and final values for pH, bicarbonate, 
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and electrolytes, and between height for age, weight for 
age, and BMI z-scores, suggesting that the medications 
associated with multidisciplinary follow-up made it 
possible to improve growth.
The exact mechanism by which indomethacin improves 
linear growth has not been well defined, without any 
evidenced relationship with the medication dose; however, 
it is clear that despite growth retardation, height can be 
recovered with treatment(19). In our study, patients who 
showed no improved height were followed up for a short 
period of time (patient four - 4 months) or low adherence 
to treatment (patient seven). Improvement can also be a 
consequence of an increase in serum potassium balance, since 
this ion is essential for longitudinal growth. The mechanism 
responsible for this has not been well established, but it may 
be associated with changes in the growth hormone secretion 
and resistance against its action(7). 
Because BS is a rare disease, there are few reports in the 
literature about nutritional data, which makes it difficult 
to establish comparisons with our results. Our study has 
a relatively long mean follow-up; however, we included 
patients who were only followed up for three months, which 
restricts the possibility of investigating the impact of the 
treatment on the disease progression in a broad manner. 
However, despite the limitation related to our small 
sample and the fact that we did not conduct any molecular 
investigations, the present study may contribute to make 
the clinical aspects and the treatment of this condition more 
widely known. After the beginning of the specific treatment, 
we found a trend of improvement in the metabolic profile 
and nutritional status, with resolution of the weight deficit in 
most patients. In conclusion, it is advisable to be aware of the 
possibility of establishing BS diagnosis so that therapeutic 
measures can be implemented as early as possible.
